Wednesday, August 24, 2011

Its #Gene #Patents Upheld, Myriad Genetics Moves to Protect Its Secrets - NYTimes.com:
Myriad Genetics retained its monopoly on a lucrative genetic test for breast cancer risk when a federal appeals court recently upheld the company’s patents on two human genes — and the validity of gene patents in general.
Enlarge This Image

But it is only a matter of time before the company’s business faces severe challenges, some experts say, because that $3,340 test is technologically outmoded, incomplete and too costly.

No comments:

Legal

Anticipate This!™ | Patent and Trademark Law Blog

FOSS Patents

Groklaw

IP Law Blog

OUT-LAW News

Patent Docs

Patent Law Practice Center

Patently-O

Philip Brooks' Patent Infringement Updates

Reexamination Alert™

Steve van Dulken's Patent blog

Tactical IP

Think IP Strategy

Software

OSNews

Slashdot

Mobile Industry

Epic Mobile News

Mobiledia

mocoNews

Android

Apple

Microsoft

International

Asia and Australia

Europe

North and South America